If serum transaminase levels remain consistently 3 times higher than the upper limit of the reference range, treatment with statins must be stopped.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20 mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80mg is recommended for secondary prevention. The graphic shows the different types of statins available.

Patients with cancer have a high risk of developing hypercalcemia, which is linked to a shortened QT interval. The QT interval can also be prolonged due to electrolyte imbalances such as hypokalemia, hypomagnesemia, and hypocalcemia, as well as hypothermia, myocardial ischemia, and congenital long QT syndrome. First-degree heart block is characterized by a fixed prolonged PR interval, while hyperkalemia is indicated by tall T waves that may be followed by flattened P waves, PR prolongation, and a sine-wave appearance. S1Q3T3, which refers to an S wave in lead I, a Q wave in lead III, and an inverted T wave in lead III, is a rare finding that is often associated with pulmonary embolism (PE), but it is not a reliable indicator of this condition.

Hypercalcaemia: Symptoms and Signs

Hypercalcaemia is a medical condition characterized by high levels of calcium in the blood. The symptoms and signs of hypercalcaemia can be remembered by the phrase ‘bones, stones, groans and psychic moans’. This means that patients with hypercalcaemia may experience bone pain, kidney stones, constipation, and changes in mood or behavior. In addition, corneal calcification and a shortened QT interval on an electrocardiogram (ECG) may also be present. Hypertension, or high blood pressure, is another common feature of hypercalcaemia. It is important to seek medical attention if any of these symptoms are present, as hypercalcaemia can lead to serious complications if left untreated.

The man’s symptoms suggest that he is experiencing cluster headaches, which typically occur once a day and cause pain around one eye. Other common symptoms include eye-watering and nasal congestion. To prevent these headaches, the man should avoid smoking and alcohol, which are known triggers. Cluster headaches usually last between 15 minutes and 2 hours and occur in clusters that can last from 4 to 12 weeks. Duration of 1-2 weeks or up to 10 days is too short, while 3-4 months or 4-6 months is too long for cluster headaches.

Cluster headaches are a type of headache that is known to be extremely painful. They are called cluster headaches because they tend to occur in clusters that last for several weeks, usually once a year. These headaches are more common in men and smokers, and alcohol and sleep patterns may trigger an attack. The pain typically occurs once or twice a day, lasting between 15 minutes to 2 hours. The pain is intense and sharp, usually around one eye, and is accompanied by redness, lacrimation, lid swelling, and nasal stuffiness. Some patients may also experience miosis and ptosis.

To manage cluster headaches, 100% oxygen or subcutaneous triptan can be used for acute treatment, with response rates of 80% and 75% respectively within 15 minutes. Verapamil is the drug of choice for prophylaxis, and a tapering dose of prednisolone may also be effective. It is recommended to seek specialist advice from a neurologist if a patient develops cluster headaches, especially with respect to neuroimaging. Some neurologists use the term trigeminal autonomic cephalgia to group a number of conditions including cluster headache, paroxysmal hemicrania, and short-lived unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT). Patients with these conditions should be referred for specialist assessment as specific treatment may be required, such as indomethacin for paroxysmal hemicrania.

Pregnant women should avoid taking ACE inhibitors like ramipril as they can lead to fetal abnormalities and renal failure. These medications are believed to hinder the production of fetal urine, resulting in oligohydramnios, and increase the likelihood of cranial and cardiac defects. However, other drugs do not pose any known risks during pregnancy and can be continued if necessary.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

Adults with polycystic kidney disease are at an increased risk of experiencing subarachnoid haemorrhage due to ruptured berry aneurysms. This is the most significant associated condition, as ADPKD is known to be linked with cerebral berry aneurysms that can rupture and cause subarachnoid haemorrhage. Liver cysts are the most common complication of ADPKD, while colonic diverticula and bowel obstruction are less frequent. Although ADPKD can cause splenic cysts and splenomegaly, this is also less common than the risk of subarachnoid haemorrhage due to cerebral berry aneurysms.

Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic condition that affects approximately 1 in 1,000 Caucasians. The disease is caused by mutations in two genes, PKD1 and PKD2, which produce polycystin-1 and polycystin-2, respectively. ADPKD type 1 accounts for 85% of cases, while ADPKD type 2 accounts for the remaining 15%. Individuals with ADPKD develop multiple fluid-filled cysts in their kidneys, which can lead to renal failure.

To diagnose ADPKD in individuals with a positive family history, an abdominal ultrasound is typically performed. The diagnostic criteria for ultrasound include the presence of two cysts, either unilateral or bilateral, in individuals under 30 years of age, two cysts in both kidneys for those aged 30-59 years, and four cysts in both kidneys for those over 60 years of age.

Management of ADPKD may involve the use of tolvaptan, a vasopressin receptor 2 antagonist, for select patients. Tolvaptan has been recommended by NICE as an option for treating ADPKD in adults with chronic kidney disease stage 2 or 3 at the start of treatment, evidence of rapidly progressing disease, and if the company provides it with the agreed discount in the patient access scheme. The goal of treatment is to slow the progression of cyst development and renal insufficiency. An enlarged kidney with extensive cysts is a common finding in individuals with ADPKD.

Understanding IgA Nephropathy

IgA nephropathy, also known as Berger’s disease, is the most common cause of glomerulonephritis worldwide. It is characterized by the deposition of IgA immune complexes in the mesangium, leading to mesangial hypercellularity and positive immunofluorescence for IgA and C3. The classic presentation is recurrent episodes of macroscopic hematuria in young males following an upper respiratory tract infection. Unlike post-streptococcal glomerulonephritis, IgA nephropathy is not associated with low complement levels and typically does not present with nephrotic range proteinuria or renal failure.

Management of IgA nephropathy depends on the severity of proteinuria and renal function. Isolated hematuria without or minimal proteinuria and normal GFR requires only follow-up to monitor renal function. Persistent proteinuria with normal or slightly reduced GFR can be treated with ACE inhibitors. If there is active disease or failure to respond to ACE inhibitors, immunosuppression with corticosteroids may be necessary. The prognosis of IgA nephropathy varies, with 25% of patients developing ESRF. Factors associated with a poor prognosis include male gender, proteinuria, hypertension, smoking, hyperlipidemia, and ACE genotype DD, while frank hematuria is a marker of good prognosis.

In haemolytic uraemic syndrome, there is a reduction in serum haptoglobins, which bind to haemoglobin, and the platelet count.

Understanding Haemolytic Uraemic Syndrome

Haemolytic uraemic syndrome (HUS) is a condition that primarily affects young children and is characterized by a triad of symptoms, including acute kidney injury, microangiopathic haemolytic anaemia, and thrombocytopenia. The majority of cases are secondary and caused by Shiga toxin-producing Escherichia coli (STEC) 0157:H7, also known as ‘verotoxigenic’ or ‘enterohaemorrhagic’. Other causes of HUS include pneumococcal infection, HIV, systemic lupus erythematosus, drugs, and cancer. Primary HUS, also known as ‘atypical’, is caused by complement dysregulation.

To diagnose HUS, doctors may perform a full blood count to check for microangiopathic hemolytic anaemia and thrombocytopenia. A fragmented blood film may also be done to look for schistocytes and helmet cells. Additionally, a stool culture may be performed to check for evidence of STEC infection, and PCR for Shiga toxins may be done.

Treatment for HUS is supportive and may include fluids, blood transfusion, and dialysis if required. Antibiotics are not recommended, despite the preceding diarrhoeal illness in many patients. Plasma exchange may be considered for severe cases of HUS not associated with diarrhoea, while eculizumab, a C5 inhibitor monoclonal antibody, has shown greater efficiency than plasma exchange alone in the treatment of adult atypical HUS.

Overall, understanding the causes, symptoms, and management of HUS is crucial for healthcare professionals to provide appropriate care for patients with this condition.

Alcoholic ketoacidosis is treated by administering saline and thiamine through an infusion. This condition is characterized by acidosis, elevated ketones, and normal or low blood glucose levels, and typically occurs in chronic alcoholics who have not eaten enough food. When the body becomes malnourished, it starts breaking down body fat, leading to the production of ketones and the development of ketoacidosis. The first steps in managing this condition involve rehydration with IV fluids like saline and administering thiamine to prevent the onset of Wernicke’s encephalopathy. It is important to note that simply replacing glucose without also replacing thiamine can be dangerous, as glucose promotes metabolism and thiamine acts as a co-factor. In contrast, IV insulin fixed rate infusion is used to manage diabetic ketoacidosis (DKA), which is characterized by high glucose levels. However, diabetic patients taking a sodium-glucose transport protein 2 inhibitor are at risk of developing euglycemic DKA. While chlordiazepoxide can help prevent alcohol withdrawal, preventing Wernicke’s should be the primary focus of initial management.

Alcoholic ketoacidosis is a type of ketoacidosis that occurs in individuals who consume large amounts of alcohol regularly. This condition is not related to diabetes and is characterized by normal blood sugar levels. Alcoholics often suffer from malnutrition due to their irregular eating habits and may vomit the food they consume, leading to starvation. When the body becomes malnourished, it starts breaking down body fat, which produces ketones and leads to ketoacidosis.

The typical symptoms of alcoholic ketoacidosis include metabolic acidosis, elevated anion gap, elevated serum ketone levels, and normal or low glucose concentration. The most effective treatment for this condition is an infusion of saline and thiamine. Thiamine is essential to prevent the development of Wernicke encephalopathy or Korsakoff psychosis. Therefore, it is crucial to provide timely and appropriate treatment to individuals suffering from alcoholic ketoacidosis to prevent further complications.

The patient is experiencing hypokalaemic metabolic alkalosis, which is a common feature of Cushing’s syndrome. This condition is caused by an excess of corticosteroids, which can be exacerbated by corticosteroid therapy. The patient’s symptoms, such as central adiposity, stretch marks, bruising, hirsutism, and acne, are all indicative of Cushing’s syndrome.

Hypokalaemic metabolic alkalosis occurs when cortisol levels are high, allowing cortisol to bind to mineralocorticoid receptors. This leads to an increase in water and sodium retention, increased potassium excretion, and increased hydrogen ion excretion. The resulting decrease in hydrogen ions causes alkalosis, while the decrease in potassium causes hypokalemia.

Hyperchloremic metabolic acidosis, on the other hand, is caused by bicarbonate loss, usually due to diarrhea. The patient does not report any gastrointestinal symptoms, so this is unlikely to be the cause. Hyperkalaemic metabolic acidosis is associated with type 4 renal tubular acidosis and hypoaldosteronism, which is not consistent with the patient’s symptoms. Hyperkalaemic metabolic alkalosis is also unlikely, as a decrease in hydrogen ions would lead to a decrease in potassium ions. Finally, hypochloremic metabolic alkalosis is most commonly caused by vomiting, which the patient did not report.

Investigations for Cushing’s Syndrome

Cushing’s syndrome is a condition caused by excessive cortisol production in the body. There are various causes of Cushing’s syndrome, including iatrogenic, ACTH-dependent, and ACTH-independent causes. To diagnose Cushing’s syndrome, doctors typically perform tests to confirm the condition and determine its underlying cause.

General lab findings consistent with Cushing’s syndrome include hypokalaemic metabolic alkalosis and impaired glucose tolerance. Ectopic ACTH secretion, which is often associated with small cell lung cancer, is characterized by very low potassium levels.

The two most commonly used tests to confirm Cushing’s syndrome are the overnight dexamethasone suppression test and the 24-hour urinary free cortisol test. The overnight dexamethasone suppression test is the most sensitive test and is used first-line to test for Cushing’s syndrome. Patients with Cushing’s syndrome do not have their morning cortisol spike suppressed. The 24-hour urinary free cortisol test measures the amount of cortisol in the urine over a 24-hour period.

To localize the cause of Cushing’s syndrome, doctors may perform additional tests such as high-dose dexamethasone suppression test, CRH stimulation, and petrosal sinus sampling of ACTH. An insulin stress test may also be used to differentiate between true Cushing’s and pseudo-Cushing’s. Overall, a combination of these tests can help diagnose Cushing’s syndrome and determine its underlying cause.

If a patient with diabetic ketoacidosis still has significant ketonaemia and acidosis after 24 hours, it is recommended to seek a review from a senior endocrinologist. This is important to consider other potential diagnoses and advise on further treatment. Treatment should aim to reduce blood ketones by approximately 1 mmol/hr and glucose by around 3mmol/hr. By 24 hours, the patient should be eating and drinking normally and can be switched to subcutaneous insulin.

Admission to ICU is not necessary at this point as the patient is relatively stable. The priority is to continue treatment and determine why the current treatment is not working, which can be best achieved with a senior review.

Continuing the current fluid replacement would be inappropriate as patients with DKA should see resolution of their condition after 24 hours of normal treatment. If the patient remains in DKA after this point, a senior review is needed.

Increasing insulin rate, as well as increasing the rate of IV fluids, should not be done without consulting a senior endocrinologist as it may lead to hypoglycaemia or dilutional hyponatraemia, respectively, which could worsen the patient’s condition.

Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. However, mortality rates have decreased from 8% to under 1% in the past 20 years. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are ultimately converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and acetone-smelling breath. Diagnostic criteria include glucose levels above 13.8 mmol/l, pH below 7.30, serum bicarbonate below 18 mmol/l, anion gap above 10, and ketonaemia.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Most patients with DKA are depleted around 5-8 litres, and isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. DKA resolution is defined as pH above 7.3, blood ketones below 0.6 mmol/L, and bicarbonate above 15.0mmol/L. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral oedema. Children and young adults are particularly vulnerable to cerebral oedema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations.

Gallstones: Symptoms, Diagnosis, and Treatment

Gallstones are a common condition, with up to 24% of women and 12% of men affected. Local infection and cholecystitis may develop in up to 30% of cases, and 12% of patients undergoing surgery will have stones in the common bile duct. The majority of gallstones are of mixed composition, with pure cholesterol stones accounting for 20% of cases. Symptoms typically include colicky right upper quadrant pain that worsens after fatty meals. Diagnosis involves abdominal ultrasound and liver function tests, with magnetic resonance cholangiography or intraoperative imaging used to confirm the presence of stones in the bile duct. Treatment options include expectant management for asymptomatic gallstones, laparoscopic cholecystectomy for symptomatic gallstones, and early ERCP or surgical exploration for stones in the bile duct. Intraoperative cholangiography or laparoscopic ultrasound may be used to confirm anatomy or exclude CBD stones during surgery. ERCP carries risks such as bleeding, duodenal perforation, cholangitis, and pancreatitis.

Chlamydia trachomatis infection is a common cause of non-specific urethritis, which presents with dysuria and urethral discharge.

The most probable diagnosis in this case is chlamydia, which may also be accompanied by gonorrhea infection. Nucleic acid amplification tests (NAAT) are used to diagnose chlamydia, and both urethral swab and first-catch urine samples can be used for this purpose. However, first-catch urine is preferred as it is less invasive and equally sensitive as a urethral swab.

While midstream urinalysis is appropriate for diagnosing urinary tract infections, the absence of haematuria or abdominal pain and the presence of urethral discharge make it less likely than chlamydia infection. Collecting discharge for microscopy and culture may be helpful in diagnosing bacterial vaginosis.

Full blood count and liver function tests are not useful in diagnosing chlamydia. However, in female patients with advanced chlamydia who have developed pelvic inflammatory disease, these tests may be crucial in diagnosing Fitz Hugh Curtis syndrome.

Understanding Urethritis in Men

Urethritis is a condition that primarily affects men and is characterized by dysuria and/or urethral discharge. However, it can also be asymptomatic in some cases. The condition is traditionally divided into two types: gonococcal and non-gonococcal urethritis (NGU), which is now referred to as non-specific urethritis (NSU). The most common causes of NSU are Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma genitalium.

To diagnose NSU, a urethral swab is taken and Gram stained to check for the presence of leukocytes and Gram-negative diplococci. Chlamydia is now increasingly diagnosed using urinary nucleic acid amplification tests. If left untreated, NSU can lead to complications such as epididymitis, subfertility, and reactive arthritis.

The management of NSU involves either a seven-day course of oral doxycycline or a single dose of oral azithromycin.

After experiencing their first seizure, individuals must wait for a period of 6 months without any further seizures before they can apply to the DVLA to have their license reinstated. However, if they have been diagnosed with epilepsy, they must wait for a minimum of 12 months without any seizures before reapplying to the DVLA for their license to be reissued. It is crucial to understand that it is the patient’s responsibility to inform the DVLA and they should not drive until they have received permission from the DVLA. It is important to note that the medical team is not responsible for informing the DVLA. It is essential to keep in mind that the requirements may differ if the individual intends to drive a public or heavy goods vehicle.

The DVLA has guidelines for drivers with neurological disorders. Those with epilepsy/seizures must not drive and must inform the DVLA. The length of time off driving varies depending on the type and frequency of seizures. Those with syncope may need time off driving depending on the cause and number of episodes. Those with other conditions such as stroke, craniotomy, pituitary tumor, narcolepsy/cataplexy, and chronic neurological disorders should inform the DVLA and may need time off driving.

If a patient with distal ulcerative colitis experiences a mild-moderate flare that does not respond to topical aminosalicylates, oral aminosalicylates should be added as an adjunct therapy. In this case, the patient’s symptoms are typical of a mild flare according to Truelove and Witt’s criteria. As his symptoms are not improving with topical treatment, oral mesalazine should be added while continuing the topical mesalazine. Oral steroids are not currently indicated for this patient’s mild flare. It is important to continue the topical therapy alongside the oral therapy for optimal management. If symptoms do not improve within two weeks, the patient should schedule a follow-up appointment.

Ulcerative colitis can be managed through inducing and maintaining remission. The severity of the condition is classified as mild, moderate, or severe based on the number of stools and presence of systemic upset. Treatment for mild-to-moderate cases of proctitis involves using topical aminosalicylate, while proctosigmoiditis and left-sided ulcerative colitis may require a combination of oral and topical medications. Extensive disease may require a high-dose oral aminosalicylate and topical treatment. Severe colitis should be treated in a hospital with intravenous steroids or ciclosporin. Maintaining remission can involve using a low maintenance dose of an oral aminosalicylate or oral azathioprine/mercaptopurine. Methotrexate is not recommended, but probiotics may prevent relapse in mild to moderate cases.

When clopidogrel cannot be used, the recommended treatment for secondary stroke prevention is a combination of aspirin 75 mg and modified-release dipyridamole. Studies have shown that this combination is more effective than taking either medication alone. Ticagrelor is not currently recommended for this purpose by NICE, and prasugrel is contraindicated due to the risk of bleeding. Oral anticoagulants like warfarin are generally not used for secondary stroke prevention, with antiplatelets being the preferred treatment.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

A reduction in flow-rate across the aortic valve and a murmur that is less audible are consequences of left ventricular systolic dysfunction.

Aortic Stenosis: Symptoms, Causes, and Management

Aortic stenosis is a condition characterized by the narrowing of the aortic valve, which can lead to various symptoms. These symptoms include chest pain, dyspnea, syncope, and a characteristic ejection systolic murmur that radiates to the carotids. Severe aortic stenosis can also cause a narrow pulse pressure, slow rising pulse, delayed ESM, soft/absent S2, S4, thrill, and left ventricular hypertrophy or failure. The most common causes of aortic stenosis are degenerative calcification in older patients and bicuspid aortic valve in younger patients.

If a patient is asymptomatic, observation is usually recommended. However, if the patient is symptomatic or has a valvular gradient greater than 40 mmHg with features such as left ventricular systolic dysfunction, valve replacement is necessary. Surgical AVR is the preferred treatment for young, low/medium operative risk patients, while TAVR is used for those with a high operative risk. Balloon valvuloplasty may be used in children without aortic valve calcification and in adults with critical aortic stenosis who are not fit for valve replacement.

In summary, aortic stenosis is a condition that can cause various symptoms and requires prompt management to prevent complications. The causes of aortic stenosis vary, and treatment options depend on the patient’s age, operative risk, and overall health.

A hyperdense middle cerebral artery (MCA) sign may be observed on CT in cases of acute ischaemic stroke, typically appearing immediately after symptom onset. This is in contrast to changes in the parenchyma, which tend to develop as the ischaemia within the tissue becomes established. An acute subdural haematoma can be identified on a CT head scan by the presence of a crescent-shaped hyperdense extra-axial collection adjacent to the frontal lobe. Raised intracranial pressure can be detected on a CT head scan by the effacement of the cerebral ventricles and loss of grey-white matter differentiation. The presence of hyperdense material in the cerebral sulci and basal cisterns is indicative of subarachnoid haemorrhage (SAH) on a CT head scan.

Assessment and Investigations for Stroke

Whilst diagnosing a stroke may be straightforward in some cases, it can be challenging when symptoms are vague. The FAST screening tool, which stands for Face/Arms/Speech/Time, is a well-known tool used by the general public to identify stroke symptoms. However, medical professionals use a validated tool called the ROSIER score, recommended by the Royal College of Physicians. The ROSIER score assesses for loss of consciousness or syncope, seizure activity, and new, acute onset of asymmetric facial, arm, or leg weakness, speech disturbance, or visual field defect. A score of greater than zero indicates a likely stroke.

When investigating suspected stroke, a non-contrast CT head scan is the first line radiological investigation. The key question to answer is whether the stroke is ischaemic or haemorrhagic, as this determines the appropriate management. Ischaemic strokes may show areas of low density in the grey and white matter of the territory, while haemorrhagic strokes typically show areas of hyperdense material surrounded by low density. It is important to identify the type of stroke promptly, as thrombolysis and thrombectomy play an increasing role in acute stroke management. In rare cases, a third pathology such as a tumour may also be detected.

The drug that can trigger haemolysis in a patient with G6PD deficiency from the given options is glipizide. G6PD deficiency is commonly caused by the consumption of fava beans/broad beans and can lead to haemolysis. Various drug classes, including sulphonamides, sulphasalazine, and sulphonylureas, among others, are also associated with haemolysis in G6PD deficiency. Glipizide is a sulphonylurea and, therefore, the correct answer. Other examples of sulphonylureas include gliclazide and glimepiride. Bisoprolol, clindamycin, and infliximab are not associated with haemolysis in G6PD deficiency. Nitrofurantoin, sulfamethoxazole, and ciprofloxacin are antibiotics that can cause haemolysis in patients with G6PD deficiency. Bisoprolol does not cause jaundice, and infliximab may rarely cause cholestasis, leading to conjugated hyperbilirubinemia, which is not associated with G6PD deficiency.

Understanding G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common red blood cell enzyme defect that is inherited in an X-linked recessive fashion and is more prevalent in people from the Mediterranean and Africa. The deficiency can be triggered by many drugs, infections, and broad (fava) beans, leading to a crisis. G6PD is the first step in the pentose phosphate pathway, which converts glucose-6-phosphate to 6-phosphogluconolactone and results in the production of nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is essential for converting oxidized glutathione back to its reduced form, which protects red blood cells from oxidative damage by oxidants such as superoxide anion (O2-) and hydrogen peroxide. Reduced G6PD activity leads to decreased reduced glutathione and increased red cell susceptibility to oxidative stress, resulting in neonatal jaundice, intravascular hemolysis, gallstones, splenomegaly, and the presence of Heinz bodies on blood films. Diagnosis is made by using a G6PD enzyme assay, and some drugs are known to cause hemolysis, while others are thought to be safe.

Comparing G6PD deficiency to hereditary spherocytosis, G6PD deficiency is more common in males of African and Mediterranean descent, while hereditary spherocytosis affects both males and females of Northern European descent. G6PD deficiency is characterized by neonatal jaundice, infection/drug-induced hemolysis, gallstones, and Heinz bodies on blood films, while hereditary spherocytosis is characterized by chronic symptoms, spherocytes on blood films, and the possibility of hemolytic crisis precipitated by infection. The diagnostic test for G6PD deficiency is measuring enzyme activity, while the diagnostic test for hereditary spherocytosis is EMA binding.

Beta-blockers are frequently prescribed for hypertension treatment, but they can lead to cold extremities as a side effect. Thiazide diuretics like bendroflumethiazide commonly cause constipation, diarrhea, dizziness, and dry mouth. Angiotensin receptor blockers such as candesartan and losartan do not typically result in cold peripheries.

Beta-blockers are a class of drugs that are primarily used to manage cardiovascular disorders. They have a wide range of indications, including angina, post-myocardial infarction, heart failure, arrhythmias, hypertension, thyrotoxicosis, migraine prophylaxis, and anxiety. Beta-blockers were previously avoided in heart failure, but recent evidence suggests that certain beta-blockers can improve both symptoms and mortality. They have also replaced digoxin as the rate-control drug of choice in atrial fibrillation. However, their role in reducing stroke and myocardial infarction has diminished in recent years due to a lack of evidence. Examples of beta-blockers include atenolol and propranolol, which was one of the first beta-blockers to be developed and is lipid soluble, allowing it to cross the blood-brain barrier.

Like all drugs, beta-blockers have side-effects, including bronchospasm, cold peripheries, fatigue, sleep disturbances (including nightmares), and erectile dysfunction. They are contraindicated in uncontrolled heart failure, asthma, sick sinus syndrome, and concurrent use with verapamil, which may precipitate severe bradycardia.

Non-Falciparum Malaria: Causes, Features, and Treatment

Non-falciparum malaria is caused by Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Plasmodium vivax is commonly found in Central America and the Indian Subcontinent, while Plasmodium ovale is typically found in Africa. Plasmodium malariae is associated with nephrotic syndrome, and Plasmodium knowlesi is found predominantly in South East Asia.

The general features of non-falciparum malaria include fever, headache, and splenomegaly. Cyclical fever every 48 hours is observed in Plasmodium vivax and Plasmodium ovale, while Plasmodium malariae has a cyclical fever every 72 hours. Ovale and vivax malaria have a hypnozoite stage, which may cause relapse following treatment.

In areas known to be chloroquine-sensitive, the World Health Organization recommends either an artemisinin-based combination therapy (ACT) or chloroquine for treatment. However, in areas known to be chloroquine-resistant, an ACT should be used. Pregnant women should avoid ACTs. Patients with ovale or vivax malaria should be given primaquine following acute treatment with chloroquine to destroy liver hypnozoites and prevent relapse.

Overall, non-falciparum malaria has distinct causes, features, and treatment options that should be considered for effective management.

Haemodialysis, sickle-cell anaemia, GP6D deficiency, and hereditary spherocytosis are conditions that can cause premature red blood cell death, leading to invalid results when measuring HbA1c levels. HbA1c is a form of haemoglobin that indicates the three-month average blood sugar level. Haemodialysis, in particular, can result in lower-than-expected HbA1c levels due to its reduction of red blood cell lifespan. Amoxicillin and citalopram are not known to affect HbA1c levels, while drugs like trimethoprim-sulfamethoxazole can increase erythrocyte destruction and cause inappropriately low HbA1c levels. Iron-deficiency anaemia, on the other hand, can cause higher-than-expected HbA1c levels, making it crucial to treat the condition to accurately track diabetic control.

Understanding Glycosylated Haemoglobin (HbA1c) in Diabetes Mellitus

Glycosylated haemoglobin (HbA1c) is a commonly used measure of long-term blood sugar control in diabetes mellitus. It is produced when glucose attaches to haemoglobin in the blood at a rate proportional to the glucose concentration. The level of HbA1c is influenced by the lifespan of red blood cells and the average blood glucose concentration. However, certain conditions such as sickle-cell anaemia, GP6D deficiency, and haemodialysis can interfere with accurate interpretation of HbA1c levels.

HbA1c is believed to reflect the blood glucose levels over the past 2-4 weeks, although it is generally thought to represent the previous 3 months. It is recommended that HbA1c be checked every 3-6 months until stable, then every 6 months. The Diabetes Control and Complications Trial (DCCT) has studied the complex relationship between HbA1c and average blood glucose. The International Federation of Clinical Chemistry (IFCC) has developed a new standardised method for reporting HbA1c in mmol per mol of haemoglobin without glucose attached.

The table above shows the relationship between HbA1c, average plasma glucose, and IFCC-HbA1c. By using this table, we can calculate the average plasma glucose level by multiplying HbA1c by 2 and subtracting 4.5. Understanding HbA1c is crucial in managing diabetes mellitus and achieving optimal blood sugar control.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

For males with myoclonic seizures, sodium valproate is the recommended first-line treatment. This patient is experiencing clonus, which is the contracting and relaxing of both upper and lower limbs. Myoclonic epilepsy is the likely diagnosis as there are no signs of loss of consciousness, incontinence, tongue-biting, or postictal fatigue. Sodium valproate is the correct choice as it has been proven effective for this use through high-quality evidence. However, it is contraindicated for women of childbearing potential due to its teratogenic effects. Ethosuximide is not appropriate as it is used for absence seizures, which are characterized by staring blankly and being unresponsive, and typically occur in children aged 3-10 years. Lamotrigine is a third-line treatment option for myoclonic seizures in men, and levetiracetam is the second-line option for men and the first-line option for women of childbearing potential. In this case, it is best to try the first-line option of sodium valproate as the patient has not yet received any treatment and is male. If sodium valproate is unsuccessful, then levetiracetam may be considered.

Treatment for Epilepsy

Epilepsy is a neurological disorder that affects millions of people worldwide. The condition is characterized by recurrent seizures, which can be debilitating and life-threatening. Treatment for epilepsy typically involves the use of antiepileptic drugs (AEDs) to control seizures and improve quality of life.

According to NICE guidelines, AEDs should be started after the second epileptic seizure. However, if a patient has a neurological deficit, brain imaging shows a structural abnormality, the EEG shows unequivocal epileptic activity, or the patient or their family considers the risk of having a further seizure unacceptable, AEDs may be started after the first seizure. It is important to note that sodium valproate should not be used during pregnancy and in women of childbearing age unless clearly necessary due to the risk of neurodevelopmental delay in children.

The choice of AEDs depends on the type of epilepsy. For generalized tonic-clonic seizures, males are typically prescribed sodium valproate, while females are prescribed lamotrigine or levetiracetam. For focal seizures, lamotrigine or levetiracetam are the first-line treatments, with carbamazepine, oxcarbazepine, or zonisamide as second-line options. Ethosuximide is the first-line treatment for absence seizures, with sodium valproate or lamotrigine/levetiracetam as second-line options. For myoclonic seizures, males are prescribed sodium valproate, while females are prescribed levetiracetam. Finally, for tonic or atonic seizures, males are prescribed sodium valproate, while females are prescribed lamotrigine.

In summary, treatment for epilepsy involves the use of AEDs to control seizures and improve quality of life. The choice of AEDs depends on the type of epilepsy, and sodium valproate should be used with caution in women of childbearing age.

Coeliac disease affects approximately 1% of the population and is managed through a gluten-free diet. As a healthcare professional, it is important to have a basic understanding of which foods contain gluten in order to advise patients on what to avoid and what is safe to eat. Safe foods for coeliac patients include corn, potatoes, and rice, as they do not contain gluten. On the other hand, foods such as barley and wheat should be avoided as they contain gluten. While oats may be tolerated by some patients, there is a risk of a reaction and should be approached with caution.

Managing Coeliac Disease with a Gluten-Free Diet

Coeliac disease is a condition that requires the management of a gluten-free diet. Gluten is found in cereals such as wheat, barley, rye, and oats. Patients with coeliac disease must avoid consuming foods that contain gluten, including bread, pasta, pastry, and beer made from barley. However, whisky made from malted barley is safe to drink as the distillation process removes proteins like gluten. Patients with coeliac disease can consume gluten-free foods such as rice, potatoes, and corn.

To ensure compliance with a gluten-free diet, doctors may check tissue transglutaminase antibodies. Patients with coeliac disease often have functional hyposplenism, which means they are more susceptible to infections. Therefore, all patients with coeliac disease are offered the pneumococcal vaccine and are recommended to have a booster every five years. Coeliac UK also recommends vaccinating against pneumococcal infection. The influenzae vaccine is given on an individual basis according to current guidelines.

Managing coeliac disease with a gluten-free diet is crucial to prevent complications and improve quality of life. By avoiding gluten-containing foods and consuming gluten-free alternatives, patients with coeliac disease can manage their condition effectively. Vaccinations against infections are also essential to protect patients with coeliac disease, who may have a weakened immune system.

When patients are suspected of having viral meningitis, doctors often prescribe antibiotics as a precaution until the results of a lumbar puncture are available. This is especially true for elderly patients or those with weakened immune systems. If a young patient presents with symptoms such as fever, headache, and neck stiffness, doctors may perform tests like Kernig’s or Brudzinski’s signs to help diagnose the condition. However, because bacterial meningitis can be very dangerous, doctors may start treatment before a definitive diagnosis is made. Even if the likelihood of bacterial meningitis is low, delaying treatment could have serious consequences for the patient. Viral meningitis is more common and less severe than bacterial meningitis, but it can be difficult to distinguish between the two based on symptoms alone. Therefore, doctors may prescribe antibiotics as a precaution if a lumbar puncture cannot be performed within an hour. In this case, intravenous ceftriaxone would be the appropriate treatment. IV fluconazole is used to treat severe fungal infections, but it is unlikely to be necessary in an otherwise healthy patient. IV amoxicillin is typically reserved for patients who are immunocompromised, under 6 months old, or over 60 years old, as it can help protect against Listeria monocytogenes.

Understanding Viral Meningitis

Viral meningitis is a condition characterized by inflammation of the leptomeninges and cerebrospinal fluid in the subarachnoid space caused by a viral agent. It is a more common and less severe condition compared to bacterial meningitis. Although approximately 3,000 cases of confirmed viral meningitis are reported yearly, the actual number of cases is likely to be much higher as patients often do not seek medical attention.

The causes of viral meningitis include non-polio enteroviruses such as coxsackievirus and echovirus, mumps, herpes simplex virus (HSV), cytomegalovirus (CMV), herpes zoster viruses, HIV, and measles. Patients at the extremes of age, immunocompromised patients, and intravenous drug users are at higher risk of developing viral meningitis.

Common symptoms of viral meningitis include headache, neck stiffness, photophobia, confusion, and fever. Focal neurological deficits on examination and seizures suggest a meningoencephalitis. A lumbar puncture is necessary to confirm the diagnosis, and cerebrospinal fluid findings in viral meningitis include lymphocyte-predominant cell differential, glucose levels of 2.8 – 4.2 mmol/L or 2/3 paired serum glucose mmol/L, and protein levels of 0.5 – 1 g/dL.

Management of viral meningitis involves supportive treatment while awaiting the results of the lumbar puncture. If there is any suspicion of bacterial meningitis or encephalitis, broad-spectrum antibiotics with CNS penetration such as ceftriaxone and acyclovir intravenously should be administered. Generally, viral meningitis is self-limiting, and symptoms improve over the course of 7 – 14 days. acyclovir may be used if the patient is suspected of having meningitis secondary to HSV. Complications are rare in immunocompetent patients.

Generalised lymphadenopathy can be caused by several conditions, including CMV and Infectious mononucleosis (IM), which are mentioned in the question. However, the presence of large swollen tonsils and a palpable mass in the left hypochondriac regions, which suggests splenomegaly, together with the patient’s history, highly suggests IM. Tonsillitis, viral throat infection, and dengue fever do not typically present with generalised lymphadenopathy or splenomegaly.

Understanding Infectious Mononucleosis

Infectious mononucleosis, also known as glandular fever, is a viral infection caused by the Epstein-Barr virus (EBV) in 90% of cases. It is most commonly seen in adolescents and young adults. The classic triad of symptoms includes sore throat, pyrexia, and lymphadenopathy, which are present in around 98% of patients. Other symptoms include malaise, anorexia, headache, palatal petechiae, splenomegaly, hepatitis, lymphocytosis, haemolytic anaemia, and a maculopapular rash. The symptoms typically resolve after 2-4 weeks.

The diagnosis of infectious mononucleosis is confirmed through a heterophile antibody test (Monospot test) in the second week of the illness. Management is supportive and includes rest, drinking plenty of fluids, avoiding alcohol, and taking simple analgesia for any aches or pains. It is recommended to avoid playing contact sports for 4 weeks after having glandular fever to reduce the risk of splenic rupture.

Interestingly, there is a correlation between EBV and socioeconomic groups. Lower socioeconomic groups have high rates of EBV seropositivity, having frequently acquired EBV in early childhood when the primary infection is often subclinical. However, higher socioeconomic groups show a higher incidence of infectious mononucleosis, as acquiring EBV in adolescence or early adulthood results in symptomatic disease.

In the case of this patient, it is probable that she is experiencing an acute relapse of her multiple sclerosis. A urine dip has been conducted to rule out a urinary tract infection, which could also cause a flare in her symptoms (known as Uhthoff’s phenomenon). As her symptoms are new and have persisted for more than 24 hours, it is likely that she requires treatment with methylprednisolone (either intravenous or oral) to manage the relapse.

While Fingolimod, Natalizumab, and Beta-interferon are all disease modifying drugs that may reduce the frequency of relapses, they are not appropriate for treating acute relapses and should only be started in secondary care with proper drug counseling.

Amantadine may be useful in managing fatigue, but it is recommended by NICE to only be trialed for fatigue once other potential causes have been ruled out. It is unlikely to be effective in treating the patient’s other symptoms.

Multiple sclerosis is a condition that cannot be cured, but its treatment aims to reduce the frequency and duration of relapses. In the case of an acute relapse, high-dose steroids may be administered for five days to shorten its length. However, it is important to note that steroids do not affect the degree of recovery. Disease-modifying drugs are used to reduce the risk of relapse in patients with MS. These drugs are typically indicated for patients with relapsing-remitting disease or secondary progressive disease who have had two relapses in the past two years and are able to walk a certain distance unaided. Natalizumab, ocrelizumab, fingolimod, beta-interferon, and glatiramer acetate are some of the drugs used to reduce the risk of relapse in MS.

Fatigue is a common problem in MS patients, and amantadine is recommended by NICE after excluding other potential causes such as anaemia, thyroid problems, or depression. Mindfulness training and CBT are other options for managing fatigue. Spasticity is another issue that can be addressed with first-line drugs such as baclofen and gabapentin, as well as physiotherapy. Cannabis and botox are currently being evaluated for their effectiveness in managing spasticity. Bladder dysfunction is also a common problem in MS patients, and anticholinergics may worsen symptoms in some patients. Ultrasound is recommended to assess bladder emptying, and intermittent self-catheterisation may be necessary if there is significant residual volume. Gabapentin is the first-line treatment for oscillopsia, which is a condition where visual fields appear to oscillate.

Patients who exhibit signs of shock and bradycardia should be administered 500 micrograms of atropine, which can be repeated up to a maximum of 3mg. In the case of this patient, who has experienced syncope and is unstable, atropine is necessary. Amiodarone is used for tachycardias, while bisoprolol is used for rate control in longstanding tachycardias. DC cardioversion is used for tachycardia, and if atropine is ineffective, transcutaneous pacing may be considered. IV saline would not be beneficial in this case, as the patient’s hypotension is caused by bradycardia rather than hypovolemia.

Management of Bradycardia in Peri-Arrest Rhythms

The 2021 Resuscitation Council (UK) guidelines highlight that the management of bradycardia in peri-arrest rhythms depends on two factors. Firstly, identifying adverse signs that indicate haemodynamic compromise, such as shock, syncope, myocardial ischaemia, or heart failure. Secondly, identifying the potential risk of asystole, which can occur in patients with complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, or ventricular pause > 3 seconds.

If adverse signs are present, Atropine (500mcg IV) is the first line treatment. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, or isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing in patients with risk factors for asystole. By following these guidelines, healthcare professionals can effectively manage bradycardia in peri-arrest rhythms and improve patient outcomes.

Understanding Henoch-Schonlein Purpura

Henoch-Schonlein purpura (HSP) is a type of small vessel vasculitis that is mediated by IgA. It is often associated with IgA nephropathy, also known as Berger’s disease. HSP is commonly observed in children following an infection.

The condition is characterized by a palpable purpuric rash, which is accompanied by localized oedema over the buttocks and extensor surfaces of the arms and legs. Other symptoms include abdominal pain, polyarthritis, and features of IgA nephropathy such as haematuria and renal failure.

Treatment for HSP involves analgesia for arthralgia, while management of nephropathy is generally supportive. There is inconsistent evidence for the use of steroids and immunosuppressants.

The prognosis for HSP is usually excellent, especially in children without renal involvement. The condition is self-limiting, but around one-third of patients may experience a relapse. It is important to monitor blood pressure and urinalysis to detect any progressive renal involvement.

Overall, understanding Henoch-Schonlein purpura is crucial for prompt diagnosis and management of the condition.

To ensure proper drug delivery, it is important to use the correct inhaler technique. This involves removing the cap, shaking the inhaler, and taking a slow breath in while delivering the dose. After holding the breath for 10 seconds, it is recommended to wait for approximately 30 seconds before repeating the dose. In this case, the individual should have waited for the full 30 seconds before taking a second dose.

Proper Inhaler Technique for Metered-Dose Inhalers

Proper inhaler technique is crucial for effective treatment of respiratory conditions such as asthma. The following guidelines are recommended by Asthma.org.uk, a resource recommended to patients by the British Thoracic Society, for using metered-dose inhalers.

To begin, remove the cap and shake the inhaler. Breathe out gently before placing the mouthpiece in your mouth. As you begin to breathe in slowly and deeply, press down on the canister and continue to inhale steadily. Hold your breath for 10 seconds, or as long as is comfortable, before exhaling. If a second dose is needed, wait approximately 30 seconds before repeating the steps.

It is important to note that the inhaler should only be used for the number of doses indicated on the label before starting a new inhaler. By following these guidelines, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.